Jtfm, Silver you have no idea how much I want to share your enthusiasm around a buyout (I’m heavily invested) but there’s something that doesn’t make much sense to me: why would they bother with an acquisition process of a relatively small player (Alim) if something as big and as transformative as Libigel was in the cards in the very near future? The addition of Alimera seems to be a lot of organisational hassle, even if accretive, and wouldn’t make a huge difference towards a potential buyer. Happy to get your views on this. Thanks
Market Data 
Markets 
AI
